Literature DB >> 21816249

The cost of vision loss in Canada. 2. Results.

Alan F Cruess1, Keith D Gordon, Lorne Bellan, Scott Mitchell, M Lynne Pezzullo.   

Abstract

OBJECTIVE: This study was conducted to provide the financial underpinnings necessary for effective planning for the provision of eye health services in Canada. Canada is facing an aging demographic and all the major eye diseases are diseases associated with aging. It is essential that we have information based on the best available data to support national and provincial vision health plans.
DESIGN: The design associated with the prevalence-based approach used in this study was outlined previously in detail in The Cost of Vision Loss in Canada: Methodology.
METHODS: The methods associated with the prevalence-based approach used in this study were previously outlined in detail in The Cost of Vision Loss in Canada: Methodology.
RESULTS: The financial cost of VL in Canada in 2007 was estimated to be $15.8 billion per annum: $8.6 billion (54.6%) represents direct health system expenditure; $4.4 billion (28.0%) was productivity lost due to lower employment, higher absenteeism, and premature death of Canadians with VL; $1.8 billion (11.1%) was the dead weight losses (DWL) from transfers including welfare payments and taxation forgone; $0.7 billion (4.4%) was the value of the care for people with VL; $305 million (1.9%) was other indirect costs such as aids and home modifications and the bring forward of funeral costs. Additionally, the value of the lost well-being (disability and premature death) was estimated at a further $11.7 billion. In per capita terms, this amounts to a financial cost of $19370 per person with VL per annum. Including the value of lost well-being, the cost is $33704 per person per annum.
CONCLUSIONS: There is a growing awareness in Canada and around the world of the impact of VL on health costs and on the economy in general. This awareness is supported by the growing number of independent studies on the cost of vision loss both nationally and globally. Because most of these studies are limited by the minimal amount of available data, the overall cost of vision loss is likely underestimated. Nevertheless, this study reports the cost of vision loss in Canada as being greater than previously reported, making the problem even more urgent to address. A comprehensive national vision health plan, that is a coordinated federal, provincial and territorial initiative dealing with all aspects of vision loss prevention, sight restoration, and vision rehabilitation is called for.
Copyright © 2011 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21816249     DOI: 10.1016/j.jcjo.2011.06.006

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  17 in total

1.  Preventing blindness: seeing is believing.

Authors:  Ken Flegel; Noni E MacDonald; Matthew B Stanbrook; Astika Kappagoda; Paul C Hébert
Journal:  CMAJ       Date:  2011-10-17       Impact factor: 8.262

2.  Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study.

Authors:  Mahyar Etminan; Farzin Forooghian; David Maberley
Journal:  CMAJ       Date:  2012-04-02       Impact factor: 8.262

3.  Neurosciences, Rehabilitation and Vision Strategic Clinical Network: Improving how Albertans see, think and live.

Authors:  Nicole McKenzie; Petra O'Connell; Chester Ho
Journal:  CMAJ       Date:  2019-12-04       Impact factor: 8.262

Review 4.  Retinal Diseases: The Next Frontier in Pharmacodelivery.

Authors:  Assaf Ben-Arzi; Rita Ehrlich; Ron Neumann
Journal:  Pharmaceutics       Date:  2022-04-21       Impact factor: 6.525

5.  Myopia prevalence in Canadian school children: a pilot study.

Authors:  Mike Yang; Doerte Luensmann; Desmond Fonn; Jill Woods; Debbie Jones; Keith Gordon; Lyndon Jones
Journal:  Eye (Lond)       Date:  2018-02-02       Impact factor: 3.775

6.  The economic burden of visual impairment and blindness: a systematic review.

Authors:  Juliane Köberlein; Karolina Beifus; Corinna Schaffert; Robert P Finger
Journal:  BMJ Open       Date:  2013-11-07       Impact factor: 2.692

Review 7.  What the comprehensive economics of blindness and visual impairment can help us understand.

Authors:  Kevin D Frick
Journal:  Indian J Ophthalmol       Date:  2012 Sep-Oct       Impact factor: 1.848

8.  Fundus autofluorescence imaging in an ocular screening program.

Authors:  A M Kolomeyer; N V Nayak; B C Szirth; A S Khouri
Journal:  Int J Telemed Appl       Date:  2012-12-19

9.  A randomised trial of non-mydriatic ultra-wide field retinal imaging versus usual care to screen for diabetic eye disease: rationale and protocol for the Clearsight trial.

Authors:  Selina L Liu; Lewis W Mahon; Neil S Klar; David C Schulz; John R Gonder; Irene M Hramiak; Jeffrey L Mahon
Journal:  BMJ Open       Date:  2017-08-03       Impact factor: 2.692

10.  The economic impact of sight loss and blindness in the UK adult population.

Authors:  Lynne Pezzullo; Jared Streatfeild; Philippa Simkiss; Darren Shickle
Journal:  BMC Health Serv Res       Date:  2018-01-30       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.